Aptevo Therapeutics Inc.
APVO | NASDAQ
$1.86
+$0.05 (+2.76%)
Sep 22, 2026, 11:48 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -0.11 | -0.05 | -0.13 | 1.47 | -1.30 | -3.87 |
PEG Ratio | 0 | 0 | 0 | -0.01 | 0.04 | 0.04 |
PS Ratio | n/a | n/a | n/a | 3.80 | 3 | 28.84 |
PB Ratio | 0 | 0.25 | 0.18 | 0.66 | 30.34 | 7.49 |
P/FCF Ratio | 0 | -0.05 | -0.19 | -0.56 | -1.65 | -4.23 |
P/OCF Ratio | 0 | -0.05 | -0.19 | -0.56 | -1.70 | -4.24 |
OCF/S Ratio | n/a | n/a | n/a | -675.08 | -176.37 | -680.39 |
Debt / Equity Ratio | 0.27 | 0.97 | 0.44 | 0.53 | 13.75 | 1.65 |
Quick Ratio | 3.82 | 1.72 | 2.64 | 3.15 | 1.51 | 3.25 |
Current Ratio | 3.82 | 1.72 | 2.64 | 3.15 | 1.51 | 3.25 |
Asset Turnover | n/a | n/a | n/a | 0.09 | 0.22 | 0.08 |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -149.40% | -507.47% | -142.47% | 44.66% | -2.34K% | -106.97% |
Return on Assets | -95.49% | -154.77% | -70.09% | 23.46% | -50.28% | -33.15% |
Return on Invested Capital | -119.55% | -262.17% | -163.91% | -104.11% | -63.86% | -62.48% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | 100% | 100% | -314.30% |
Net Profit Margin | n/a | n/a | n/a | 257.77% | -231.51% | -411.93% |
Pretax Profit Margin | n/a | n/a | n/a | 225.24% | -239.25% | -717.64% |
Operating Profit Margin | n/a | n/a | n/a | -919.75% | -174.10% | -638.06% |
FCF Margin | n/a | n/a | n/a | -676.01% | -182.17% | -682.43% |
EBITDA Margin | n/a | n/a | n/a | 254.17% | -229.94% | -607.75% |
Add to Watchlist
Select watchlists to add or remove APVO